Cited by

• PRDM1 is a tumor suppressor gene in natural killer cell malignancies.

  Küçük C, Iqbal J, Hu X, Gaulard P, De Leval L, Srivastava G, Au WY, McKeithan TW, Chan WC. Küçük C, et al. Proc Natl Acad Sci U S A. 2011 Dec 13;108(50):20119-24. doi: 10.1073/pnas.1115128108. Epub 2011 Dec 5. Proc Natl Acad Sci U S A. 2011. PMID: 22143801 Free PMC article.
• Resistance to cisplatin and analogues: mechanisms and potential clinical implications.

  de Graeff A, Slebos RJ, Rodenhuis S. de Graeff A, et al. Cancer Chemother Pharmacol. 1988;22(4):325-32. doi: 10.1007/BF00254240. Cancer Chemother Pharmacol. 1988. PMID: 3048763 Review.
• Glycosylation of procathepsin L does not account for species molecular-mass differences and is not required for proteolytic activity.

  Smith SM, Kane SE, Gal S, Mason RW, Gottesman MM. Smith SM, et al. Biochem J. 1989 Sep 15;262(3):931-8. doi: 10.1042/bj2620931. Biochem J. 1989. PMID: 2480110 Free PMC article.
• Structure-Activity Relationship of the Thiacalix[4]arenes Family with Sulfobetaine Fragments: Self-Assembly and Cytotoxic Effect against Cancer Cell Lines.

  Yakimova L, Kunafina A, Nugmanova A, Padnya P, Voloshina A, Petrov K, Stoikov I. Yakimova L, et al. Molecules. 2022 Feb 17;27(4):1364. doi: 10.3390/molecules27041364. Molecules. 2022. PMID: 35209152 Free PMC article.
• Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells.

  Kiehntopf M, Brach MA, Licht T, Petschauer S, Karawajew L, Kirschning C, Herrmann F. Kiehntopf M, et al. EMBO J. 1994 Oct 3;13(19):4645-52. doi: 10.1002/j.1460-2075.1994.tb06787.x. EMBO J. 1994. Retraction in: EMBO J. 1997 Jul 1;16(13):4153. doi: 10.1093/emboj/16.13.4153. PMID: 7925305 Free PMC article. Retracted.